SAN DIEGO, CA., June 6, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of John Huynh, Ph.D., as the Company’s first Chief Technology Officer. Dr. Huynh brings nearly two decades of experience leading and developing specialized manufacturing and technical operations across a host of therapeutic modalities, including adeno-associated virus gene therapy. At IconOVir, Dr. Huynh will be responsible for the development of manufacturing, process development, and technical operations, while contributing to CMC quality control in support of the Company’s emerging OV-based therapeutic pipeline.
“We are delighted to welcome John to IconOVir as we expand and accelerate our manufacturing processes, and work towards our goal of bringing the next generation of OV therapy to cancer patients in need,” said Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir. “John brings extensive experience leading technical development, clinical and commercial manufacturing, which is critical to our near-term development priorities as we prepare to file an investigational new drug application for our lead product candidate, ICVB-1042. We look forward to his many contributions as we execute on our mission of curing cancer and restoring life to every patient, everywhere.”
Dr. Huynh joins IconOVir from Ring Therapeutics, where he served as Senior Vice President of Technical Operations and was responsible for overseeing process and analytical development, manufacturing, quality control, CMC and supply chain. Prior to joining Ring, he was a Vice President of Gene Therapy Technical Operations at PTC Therapeutics, where he helped establish and grow their gene therapy CMC group and made significant contributions to enable the marketing authorization of Upstaza. Before that, Dr. Huynh held positions of increasing responsibilities at Merck, WuXi AppTec, and the University of Pennsylvania Gene Therapy Program, focusing his career on process development and life-cycle management of viral vaccines and vectors. Dr. Huynh holds a Ph.D. in Biomedical Engineering from Cornell University and a B.S. in Biomedical Engineering from the University of Texas at Austin.
“I am honored to join IconOVir at such an exciting time and contribute to the development of the next generation of OV therapy for cancer patients,” said Dr. Huynh. “I believe product candidates built using IconOVir’s proprietary Adenovirus engineering platform, which employs a modular approach to rapidly design, test, and select the best viruses, have an unparalleled opportunity to potentiate OVs as a clinical modality and, therefore, to deliver medicines that can better treat a broad range of cancers. I look forward to supporting the full potential of IconOVir’s platform technology and product candidates by expanding and integrating our manufacturing processes and technical operations.”
IconOVir is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. IconOVir’s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients. For more information, please visit www.iconovir.com and follow IconOVir on LinkedIn.
Stern Investor Relations, Inc.